Zydus Lifesciences Limited announced on March 11, 2025, that it entered into an agreement to acquire a majority stake in Amplitude Surgical. Reports state that Zydus Lifesciences has a tender offer agreement with PAI Partners, Amplitude Surgical’s management and two minority shareholders. Under the agreement, Zydus Lifesciences would acquire 85.6% of Amplitude Surgical for €256.8M ($277.4M).
Amplitude Surgical is a European surgical device maker that specializes in lower-limb orthopedic technologies. Amplitude Surgical also provides related systems and services, such as the AMPLIVISION® Computer Assisted Surgery system, the i.M.A.G.E.® single-use made-to-measure instrument system and the E.T.O.I.L.E® technology platform. The systems purportedly aid in increasing fitting accuracy and enabling a less-invasive surgical approach. Amplitude Surgical has reportedly experienced significant growth over the last four years driven by new product development, international growth, investments in manufacturing capabilities and R&D.
Regarding the discussion, Dr. Sharvil Patel, Zydus Lifesciences’ Managing Director, said “Our commitment to quality excellence, continuous investments in R&D and expertise in manufacturing will guide our foray into highly specialised MedTech products, adding a new dimension to our operations.” Dr. Patel further stated that Zydus Lifesciences sees in the potential deal “several medium-term and long-term growth opportunities with respect to portfolio, capabilities, manufacturing and geographies.”
The agreement is subject to entering into definitive agreements for completion of the Block Acquisition. The Block Agreement is expected to be completed and submitted by June 2025 for approval by the Autorité des Marchés Financiers (AMF), which is the securities commission in France.
Zydus Lifesciences’ press release is available here. Amplitude Surgical’ s press release is available here. PAI Partner’s press release is available here.
